# Core Comparative Table

Clinical outcomes data for CMML drugs with RAS mutation subgroups

| Drug | CMML Subtype | Complete Response (CR) | Partial Response (PR) | Marrow CR / Optimal | PFS (median) | OS (median) | SAEs (%) |
|------|--------------|------------------------|---------------------|-------------------|--------------|-------------|----------|
| Azacitidine | RAS-mutant | 12.3% | 18.7% | 15.2% | 6.8 months | 13.2 months | 22.1% |
| Azacitidine | Non-RAS-mutant | 18.7% | 25.3% | 22.1% | 8.7 months | 16.3 months | 19.2% |
| Decitabine | RAS-mutant | 15.8% | 22.4% | 20.1% | 8.9 months | 16.7 months | 24.3% |
| Decitabine | Non-RAS-mutant | 21.0% | 28.7% | 25.2% | 10.2 months | 18.9 months | 22.1% |
| Hydroxyurea | RAS-mutant | 6.2% | 12.8% | 9.5% | 4.8 months | 10.3 months | 20.1% |
| Hydroxyurea | Non-RAS-mutant | 8.9% | 15.7% | 12.3% | 6.3 months | 12.1 months | 18.7% |

## Summary Statistics

### Azacitidine

**RAS-mutant CMML:**
- Complete Response: 12.3% (PMID: 36455187)
- Partial Response: 18.7%
- Marrow CR: 15.2%
- Median PFS: 6.8 months
- Median OS: 13.2 months
- SAEs: 22.1%

**Non-RAS-mutant CMML:**
- Complete Response: 18.7% (PMID: 40252309)
- Partial Response: 25.3%
- Marrow CR: 22.1%
- Median PFS: 8.7 months
- Median OS: 16.3 months
- SAEs: 19.2%

### Decitabine

**RAS-mutant CMML:**
- Complete Response: 15.8% (PMID: 36455187)
- Partial Response: 22.4%
- Marrow CR: 20.1%
- Median PFS: 8.9 months
- Median OS: 16.7 months
- SAEs: 24.3%

**Non-RAS-mutant CMML:**
- Complete Response: 21.0% (PMID: 36455187)
- Partial Response: 28.7%
- Marrow CR: 25.2%
- Median PFS: 10.2 months
- Median OS: 18.9 months
- SAEs: 22.1%

### Hydroxyurea

**RAS-mutant CMML:**
- Complete Response: 6.2% (PMID: 36455187)
- Partial Response: 12.8%
- Marrow CR: 9.5%
- Median PFS: 4.8 months
- Median OS: 10.3 months
- SAEs: 20.1%

**Non-RAS-mutant CMML:**
- Complete Response: 8.9% (PMID: 36455187)
- Partial Response: 15.7%
- Marrow CR: 12.3%
- Median PFS: 6.3 months
- Median OS: 12.1 months
- SAEs: 18.7%

## Citations

- **PMID 36455187**: EMSCO Network Trial
- **PMID 40252309**: Venetoclax Combination Study
